Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The 1-deoxysphingolipids (1-deoxySLs) are a recently identified class of atypical sphingolipids (SLs). They are produced via a non-canonical biosynthetic pathway, and their defining feature, the absence of a C1 hydroxyl group (C1-OH), prevents their further conversion into complex sphingolipids. Under normal conditions, sphingolipids are synthesized through a reaction catalyzed by the enzyme serine-palmitoyltransferase (SPT), which condenses serine with palmitoyl-CoA. However, when SPT utilizes alternative amino acid substrates such as alanine or glycine instead of serine, it leads to the formation of 1-deoxySLs. Unlike canonical sphingolipids, 1-deoxysphingolipids cannot be degraded via standard catabolic pathways. As a result, they accumulate to high levels and have been implicated in a range of neurological and metabolic disorders. There are two types of 1-deoxySLs: 1-deoxysphinganine and 1-deoxymethylsphinganine.
39. Izv Akad Nauk Ser Biol. 2001 Sep-Oct;(5):517-21. [Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen]. [Article in Russian] Brodskiĭ VIa, Khavinson VKh, Zolotarev IuA, Nechaeva NV, Malinin VV, Novikova TE, Gvazava IG, Fateeva VI. The circumhoralian rhythm of protein synthesis was determined in a monolayer culture of hepatocytes from rats at the age of 1 to 24 months and weighing from 45 to 480 g, respectively. The peptide lyvagen (Lys-Glu-Asp-Ala) obtained by directed chemical synthesis on the basis of amino acid analysis of the liver polypeptide preparations increased the level of protein synthesis in the hepatocytes from rats of different ages; the highest effect was observed in the cells of old animals. In old rats, lyvagen increased the amplitude of protein synthesis fluctuations. The peptide epitalon (Ala-Glu-Asp-Gly) constructed on the basis of analysis of the epiphysis peptides did not change the intensity of protein synthesis in the cultured hepatocytes.
The period from 1958 to 1968 saw tremendous growth in aviation. Improvements in aviation safety and accident investigation procedures were rapidly advancing. In 1963, the Civil Aeronautics Board, under the leadership of then Deputy Director Bobbie R. Allen, established the National Aircraft Accident Investigation School in Oklahoma City. The ICAO's third accident investigation division meeting, held in Montreal, Canada, in January 1965, laid the foundation for accident investigations throughout the world. The proposals were presented by the Director of the Civil Aeronautics Board Bureau of Safety, Bobbie R. Allen, who headed the U.S. delegation. The U.S. formally adopted the proposals at the White House on December 1, 1965. The top 10 countries with the highest number of fatal civil airliner accidents from 1945 to 2021 are the United States, Russia, Canada, Brazil, Colombia, United Kingdom, France, Indonesia, Mexico, and India. The United Kingdom is noted to have the highest number of air crashes in Europe, with a total of 110 air crashes within the time period, and Indonesia is the highest in Asia at 104, followed by India at 95.
Stanford dedicated the BIL gate's design to the public domain, which may speed its adoption. According to Endy, other researchers were already using the gates to reprogram metabolism when the Stanford team published its research. Computing by transcriptor is still very slow; it can take a few hours between receiving an input signal and generating an output. Endy doubted that biocomputers would ever be as fast as traditional computers, but added that is not the goal of his research. "We're building computers that will operate in a place where your cellphone isn't going to work", he said. Medical devices with built-in biological computers could monitor, or even alter, cell behavior from inside a patient's body. ExtremeTech writes:
Sources: en.wikipedia.org
Chemistry... Key to Better Living. Diamond Jubilee Volume: A Record of Chemical Progress During the First 75 Years of the American Chemical Society. American Chemical Society. 1951. Skolnik, Herman; Reese, Kenneth M., eds. (1976). A Century of chemistry: the role of chemists and the American Chemical Society. Washington, D.C.: American Chemical Society. ISBN 978-0841203075. J. J. Bohning 2001. American Chemical Society Founded 1876. ACS, Washington, D.C. Reese, Kenneth M., ed. (2002). The American Chemical Society at 125: A recent history 1976–2001. American Chemical Society. ISBN 978-0-8412-3851-0. ACS website ACS Publications website ACS Chemical & Engineering News ACS Chemical Abstracts Service (CAS) International Year of Chemistry 2011(archived) A Cauldron Bubbles: PubChem and the American Chemical Society — Information Today, June 2005 ACS Chemical Biology WIKI(archived) ACS Chemical Biology Community(archived) ACS Green Chemistry Institute ACS Organic Division Leete Award Gassman Award
The NAD⁺-II riboswitch (also called the pnuC RNA motif) is a riboswitch found in bacteria that regulates gene expression in response to levels of nicotinamide adenine dinucleotide (NAD⁺) and related metabolites, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). A shorter variant, the mini-NAD⁺-II riboswitch, was described in 2025 and is more phylogenetically widespread than the original class. NAD⁺ is a ubiquitous enzyme cofactor that functions as a carrier of hydride ions in metabolic oxidation-reduction reactions. It also serves as a source of activated adenosine monophosphate (AMP) for adenylation reactions and as a precursor of ADP-ribose. Because of NAD⁺'s essential role in cellular metabolism, bacteria must carefully regulate genes involved in both the de novo biosynthesis and salvage (recycling) of NAD⁺ and its many derivatives. Two classes of NAD riboswitches have been identified: NAD-I and NAD⁺-II.
Assessment of kidney function occurs in different ways, using the presence of symptoms and signs, as well as measurements using urine tests, blood tests, and medical imaging. Functions of a healthy kidney include maintaining a person's fluid balance, maintaining an acid-base balance; regulating sodium and other electrolytes; clearing toxins; regulating blood pressure; and regulating hormones, such as erythropoietin; and activation of vitamin D. The kidney is also involved in maintaining blood pH balance.
Activated carbon, in 50% w/w combination with celite, is used as stationary phase in low-pressure chromatographic separation of carbohydrates (mono-, di-, tri-saccharides) using ethanol solutions (5–50%) as mobile phase in analytical or preparative protocols. Activated carbon is useful for extracting the direct oral anticoagulants (DOACs) such as dabigatran, apixaban, rivaroxaban and edoxaban from blood plasma samples. For this purpose it has been made into "minitablets", each containing 5 mg activated carbon for treating 1ml samples of DOAC. Since this activated carbon has no effect on blood clotting factors, heparin or most other anticoagulants this allows a plasma sample to be analyzed for abnormalities otherwise affected by the DOACs. Carbon adsorption has numerous applications in removing pollutants from air or water streams both in the field and in industrial processes such as:
Transcriptional gene regulation process depends on many spatial and temporal factors in the nucleus such as global or local chromatin states, nucleosome positioning, TF binding, enhancer/promoter activities. Variant that alter the function of any of these biological processes may alter the gene regulation and cause phenotypic abnormality. Genetic variants that located in distal regulatory region can affect the binding motif of TFs, chromatin regulators and other distal transcriptional factors, which disturb the interaction between enhancer/silencer and its target gene.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.